29 March 2010

Computers in Medical Education



Computers in Medical Education
Roles of computers in medical education
* Provide facts and information
* Teach strategies for applying knowledge appropriately in medical situations
* Encourage the development of lifelong learning skills

Goals
* Students must learn about physiological processes
* Must understand the relationship between observed illnesses and underlying processes
* Must learn to perform medical procedures
* Must understand the effects of interventions on health outcomes

Basic curriculum
* Premedical requirements
* Medical school
o Basic
+ Physiology
+ Pathophysiology
o Clinical
* Residency
* CME

Teaching strategies
* Lecture
* Interactive

Process
* Presentation of a situation or body of facts containing core knowledge
* Explanation of important concepts and relationships
* How does one derive the concepts
* Why they are important
* Strategy for guiding interaction with the patient

Weaknesses of traditional approach
* Rapid knowledge growth
* Reliance on memorization rather than problem solving
* Reliance on lecture method

Terms
* Computer assisted learning
* Computer based education
* Computer assisted instruction

Advantages of computers in medical education
* Computer can augment, enhance or replace traditional teaching methods
o Rapid access to body of information
+ Data
+ Images
+ Immersive interfaces
o Any time, any place, any pace
o Simulated clinical situation

Advantages
* Interactive learning
o Active vs. passive solving
* Immediate student specific feedback
o Correct vs. incorrect, tailored response
* Tailored instruction
o Focus on areas of weakness
o Request help in interpretation
* Objective testing
o Permits standardized testing
o Self-evaluation
* Fun!

Experimentation
* Safe exploration of what-if in a well done scenario
o You can do things with simulated patients you can’t do with real ones

Case variety
* The ability to experience disease scenarios one otherwise wouldn’t see
o Simple: diabetes
o Complex: multiple disease, multiple medications
Time
* Manage diseases as they evolve over time
o Rapidly evolving problems
o Chronic diseases

Problem-solving competency
* Book smart vs. real-world
* Memorization vs. thinking
* Testing
* Right answer vs. cost-effective vs. safest vs.quickest (fewest steps)

Board examinations
* USMLE test
* CME testing

History of CAI
* Pioneering research in the 1960’s
o Ohio State
+ Tutorial evaluation system
# Constructed choice, T/F, multiple choice, matching or ranking questions
# Immediate response evaluation
# Positive feedback
# Corrective rerouting
+ Authoring language
History
* Barnett MGH 1970
o Simulated patient encounters
+ 30 simulated cases
o Mathematical modeling of physiology
+ Warfarin, insulin, Marshall
o Dxplain
* University of Illinois
o Computer aided simulation of the patient encounter
+ Computer as patient
+ Natural language encounter
* Illinois 1970’s
o Programmed logic for automated teaching (PLATO)
+ Plasma display (required specialized equipment)
+ Combination of text, graphics and photos
o TUTOR authoring language
* University of Wisconsin
o Used simulated case scenarios and estimated the efficiency of the student in arriving at a diagnosis (cost-effectiveness)
* Initial installations site limited
* Subsequent modem dial-up
* Proliferation of medical CAI, CME development entities
* Development of the internet
o Initial material bandwidth limited
o Increasing use of streaming video

Modes of CAI
* Drill and practice
* Didactic
Modes
* Discrimination learning
* Exploration vs. structures interaction
o Hyperlink analogy
o Requires feedback/guidance
* Constrained vs. unconstrained response
o Student may have a pre-selected set of possible response (learn to answer questions)
o Student may be able to probe system using natural language
* Constructive
o Put the body together from pieces of anatomy
Simulation
* Static vs. dynamic
Static simulation
Dynamic simulation
Feedback and guidance
* Feedback
o Correct vs. incorrect
o Summaries
o References
* Guidance
o Tailored feedback
o Hints
o Interactive help
Intelligent tutoring
* Sophisticated systems can
o Intervene if a student goes down an unproductive path
o Gets stuck
o Appears to misunderstand a detail
o Mixed initiative systems
o Coaching vs. tutoring
Graphics and Video
* Storage of images, video etc as part of a multimedia stream
o General appearance
o Skin lesions
o Xrays
o Sounds (cardiology, breath sounds)
Authoring systems
* Generic authoring systems
o McGraw Hill, Boeing
o Simple (constraints) vs. comprehensive (difficult to master)

Examples
* USMLE
* Lister Hill
* Stanford anatomy
* Digital anatomy
* Penn curriculum
* Medical matrix
Continuing medical education
* Echo
* PAC
* CME
Simulators
* ACLS
* Visible human
* Eye simulator
* Other simulators
Future
* Forces for change
* Impediments
o Cost
o Immaturity of authoring tools
o Bandwidth
o Barriers to sharing
+ Institutional jealousy
+ Copyright
* Lack of standard approach
o Authoring software
o Platform
* Explicit integration of CAI into curriculum
* Access to PC’s and LAN

Computers in Medical Education.ppt

Read more...

Radiation Safety Oversight of Surgical Procedures



Radiation Safety Oversight of Surgical Procedures Involving the Use of RAM
By: René Michel, M.S., RSO
VA San Diego Healthcare System, San Diego, CA

Introduction
* The objective of this presentation is to review the various Radiation Safety aspects of a typical medical procedure that involves the use of radiological agents.
* Lymphoscintigraphy (LS) is a medical procedure for the treatment of malignant melanoma and mamma-carcinoma.
* The goal is to identify which sentinel lymph nodes (SLN) have been infiltrated by tumor cells
* The objective of this presentation is to determine what basic radiation safety controls are needed.
* ALARA, dosimetry, contamination control, radioactive waste, etc.

Outline
* Radioactive Drugs Used
* Overview of the Procedure
* Radiation Exposure
* Contamination Control
* Recommendations

Radioactive Drugs
* Many radiopharmaceuticals have been evaluated for and used in LS studies
* The ideal drug, must have the following characteristics:
* Small and uniform particle size
* Short half-life
* Low LET
* Appropriate energy for gamma imaging
* 198Au colloid was one of the first widely used drugs in LS
198Au Characteristics
Particle size: 3-5 nm
Half-life: 2.7 d
Emissions: 412 keV photons plus beta particles
* 198Au was replaced by other agents with the increased availability of 99mTc
* Antimony trisulfide, albumin, human serum albumin, sulfur colloid and nano-colloid
99mTc Characteristics
Particle size: 3-90,000 nm
Half-life: 6 h
Emissions: 140 keV photons

Procedure Overview
* There are three stages in Sentinel Node LS
1) Lymphatic Mapping
2) Intradermal Blue Dye Injection
3) SLN Biopsy
Lymphatic Mapping
* The surgeon injects about 1 mCi of 99mTc unfiltered sulfur colloid intradermally near the lesion.
* The colloid is taken up by the lymphatic system and the patient is imaged with a conventional gamma camera.
* About 20 min from injection dynamic scanning is performed
* A late phase scanning done 90 min after injection shows the location of the SLNs.
* The location of the node is marked on the skin of the patient

Blue Dye Injection
* The patient is moved to the OR to perform biopsy
* To assist in identifying the nodes draining the site of interest, a blue dye is injected

SLN Biopsy

* A surgeon uses the skin mark and a scintillation probe to relocalize the highest area of uptake
* A dissection is performed through soft tissue to remove “hot” nodes located by the gamma probe
* All excised nodes are sent to the pathology lab for histological examination to asses for invasion by tumor cells

Radiation Exposure
* Nuclear Medicine personnel are excluded from this evaluation, they are already closely monitored.
* Radiation exposure to OR and Pathology personnel and the potential for spread of contamination are considered the main radiation safety concerns.

Hazards Control-Radiation Exposure
* The expected radiation exposure to personnel from handling SLN radioactive specimens is very small
* 10-15 SLN procedures/year are performed in most large medical centers
* Several studies have documented dosimetry data
Average whole-body radiation dose equivalent/procedure for hospital personnel from malignant melanoma and mamma-carcinoma SLN surgery with typical activities.
* A surgeon's hand dose has been reported to be 10 mrem (Miner et al. 1999)
* The pathologist’s hand dose is even smaller, ~ 4-6 mrem (Veronesi et al.1999)

Hazards Control- Contamination
* The residual activities a day post surgery are <0.3 mCi for tumor-specimens and <50 nCi for SNLE (Kopp and Wengenmair 2002). * These activities are relatively fixed to the tissue, they do not produce contamination that exceeds the allowed levels. * Standard universal precautions used to prevent infections are sufficient to avoid any kind of incorporation in the bodies of those handling specimens. Specimen Control * Under 10 CFR 20.1905 (NRC 2002), labeling is not required for containers holding less than 1.0 mCi of Tc-99m * Labeling is also exempted if only authorized personnel have access to containers, provided a written record identifies the contents. * Specimen quarantine before gross examination is unnecessary since the level of exposure to personnel is not a safety concern. * Despite the simplicity of the guidelines, each institution is expected to develop and implement procedures for handling radioactive specimens. * Awareness training documentation for all individuals handling these specimens is also necessary. Recommended Guidelines 1. Follow standard universal precautions (e.g., wear hospital gown, surgical gloves, etc.). 2. Using forceps, place all radioactive specimens removed from the patient in a sealed container. 3. In addition to the patient’s name and specimen number, label all resected primary site specimens with the name of the isotope (e.g., 99mTc), date and time when it was collected 4. Maintain security of specimens at all times 1. Upon completion of the surgical procedure, all instruments (e.g., forceps, scalpels, etc.) having had direct contact with the radioactive specimens should be cleaned following standard procedures. 2. All specimens should follow the normal biomedical waste stream and be surveyed before disposal to ensure that radiation levels are not distinguished from background References Radiation Safety Oversight of Surgical Procedures.ppt

Read more...

Emerging Infections and Medical Procedures



Emerging Infections and Medical Procedures
By:Lennox K. Archibald, MD, PhD, FRCP
Hospital Epidemiologist, University of Florida

Parasitic Infections:
Clinical Manifestations, Diagnosis and Treatment

The Reality
* 1.3 billion persons infected with Ascaris (1: 4 persons on earth)
* 300 million with schistosomiasis
* 100 million new malaria cases/yr
* At UCLA, 38% of pediatric and dental clinic children harbored intestinal parasites

Infections Deaths

Parasites
* Organisms that cannot survive outside their host, AND they cause some harm to the host.
* Contrast with commensal organisms
* Incredibly complex organisms
* Consider the struggle for survival from the perspective of a parasite

Giardia
Giardiasis (G. lamblia)
* Should be suspected in prolonged diarrhea
* Contaminated water often implicated—outbreaks
* Campers who fail to sterilize mountain stream water
* Person-person in day care centers
* MSM
* Symptoms usually resolve spontaneously in 4-6 weeks
* Tests of choice
o Examination of concentrated stools for cysts (90% yield after 3 samples); usually no PMNs
o Stool ELISA, IF Antigen (up to 98% sensitive/90-100% specific)
o Consider aspiration of duodenal contents--trophozoites
* Treatment: Metronidazole for 5-7 days

Entamoeba histolytica
* One of 7 amoebae commonly found in humans
* Only one that causes significant disease
* Causes intestinal disease (diarrhea and dysentery) and extra-intestinal disease (liver primarily)
* In US, often seen in institutionalized patients, MSM, tourists returning from developing countries, patients with depressed cell mediated immunity
Cyst (wet mount)
* Diagnostic smear: trophozoites in liquid stools, cysts in formed stools
* IHA important in liver abscess
o Intestinal: 95% predictive of active infection
o Extra-intestinal: 100% predictive of active I infection

Amoebiasis: Clinical Manifestations
* Symptoms depend on degree of bowel invasion
o Superficial: watery diarrhea and nonspecific GI complaints
o Invasive: gradual onset (1-3 weeks) of abdominal pain, bloody diarrhea, tenesmus
* Fever is seen in minority of patients
* Can be mistaken for ulcerative colitis
* Steroids can dramatically worsen and precipitate toxic megacolon
* Amebic liver abscesses
o RUQ pain, pain referred to right shoulder
o High fever
o Hepatomegaly (50%)

Amoebic abscess—remember…
* Can occur in lung, brain, spleen
* That stool is merely a convenient vehicle passing by
* Amoebae live the bowel wall
* Direct observation preferable to mere examination of stool
* Trophozoites best seen in direct scrapings of ulcers
* Liquifaction of liver cells
* Do not contain pus
* Anchovy paste sauce
* Culture of contents usually sterile
* Liver affected
o 53%--right lobe
o 8%--left lobe

Amoebiasis (Entamoeba histolytica)
Treatment
* Most respond to metronidazole
* Open surgical drainage should be avoided, if at all possible

Cryptosporidium
Cryptosporidium parvum
* Causes secretory diarrhea: 10 liter/day
* Significant cause of death in HIV/AIDS
* Animal reservoirs
* Incubation period: 5-10 days
* Infants and younger children in day-care centers
* Unfiltered or untreated drinking water
* Farming practices: lambing, calving, and muck-spreading
* Sexual practices that brings a person into oral contact with feces of an infected individual
* Nosocomial setting with other infected patients or health-care employees
* Veterinarians: contact with farm animals
* Travelers to areas with untreated water
* Living in densely populated urban areas
* Owners of infected household pets (rare)

Diagnosis and Treatment
* Best diagnosed by stool exam
* There is no known effective treatment-nitazoxamide shortens duration of diarrhea
o Infectious disease specialist - for consideration of antiparasitic and antiretroviral therapy
o Gastroenterologist - ERCP and sphincterotomy; endoscopy sometimes required for diagnosis
o General surgeon - suspected acalculous cholecystitis

Malaria
Falciparum vs. Vivax
* Location: Falciparum confined to tropics and subtropics; vivax more temperate
* Falciparum infects RBC of any age; others like reticulocytes; only 2% infected cells
* Falciparum infected RBCs stick to vascular endothelium causing capillary blockage; fewer schizonts in the periphery, heavy pigment deposition, cerebral and renal disease
* Vivax and Ovale may reinfect hepatocytes, leading to a persisting tissue phase, causing relapses
* Sickle cell trait protects against Falciparum
Malaria: Genetic susceptibility
* Two genetic traits associated with decreased susceptibility to malaria
o Absence of Duffy blood group antigen blocks invasion of Plasmodium vivax
+ Significant number of Africans
o Persons with sickle cell hemoglobin are resistant to P. falciparum
+ Sickle cell disease and trait

Malaria: Clinical manifestations
* Non-specific, flu-like illness
* Incubation
* Fever is the hallmark of malaria
* Fever occurs after the lysis of RBCs and release of merozoites
* Febrile paroxysms have 3 classic stages
* Other symptoms depend upon the strain of malaria
* P. vivax, ovale and malariae: few other sxs
* P. falciparum:
* Always suspect malaria in travelers from developing countries who present with:
o Influenza-like illness
o Jaundice
o Confusion or obtundation

Diagnosis
* Giemsa-stained blood smear
* P. falciparum:
* Others:
* Examine blood on 3-4 successive days
* Key of diagnosis is to identify P. falciparum
* New assays: o ELISA for antigen, immunoassay for LDH, PCR
* Anemia, elevated LDH, increased reticulocytes, thrombocytopenia
* Elevated unconjugated bilirubin without increases in hepatic enzymes
* Elevated serum creatinine, proteinuria, hemoglobinuria, hypoglycemia

Differences in strains
* P. falciparum
* P. vivax and ovale
* P. malariae

Early troph--ring
Mature troph
Schizont
Gametocyte
Treatment
* P. falciparum malaria can be fatal if not promptly diagnosed and treated
* Pts with no immunity against P. falciparum require hospitalization
o Pregnant women, young children, elderly
* Non- P. falciparum malaria rarely requires hospitalization
* Widespread drug resistance dictates regimen (www.cdc.gov/travel; CDC malaria hot line: 770-488-7788).
* Uncomplicated malaria
o Drug options
+ Chloroquine phosphate
+ Mefloquine
+ Quinine sulfate plus doxycycline
+ Atovaquone plus proguanil (AP)
+ Artemisin derivatives
* P. vivax, ovale, malariae, chloroquine-susceptible falciparum
+ Chloroquine
+ Primaquine

Prevention
* Chloroquine
* Mefloquine
* Doxycycline
* Atovaquone plus proguanil (AP)
* Screens, nets
* 30-35% DEET
* permethrin spray for clothing and nets

And don’t forget baggage malaria!
Leishmaniasis
* Tropical areas where phlebotomine sandfly is common:
o South America
o India
o Bangladesh
o Middle East
o East Africa
* Sandfly introduces flagellated promastigote into human ingested by macrophages develops into nonflagellated amastigote
* Intracellular parasite controlled by Th1-type CD8+ response
Leishmaniasis: Clinical Manifestations
* 3 forms: visceral, cutaneous, mucosal
* A single species can produce more than one syndrome, and each syndrome is caused by multiple different species
* Visceral (kala azar)
o Species most prevalent in different places
# L. donovani – India
# L. infantum – Mid East
# L. chagasi – Latin America
# L. amazonensis -- Brazil
* Cutaneous
* Mucosal
Visceral Leishmaniasis
* Dissemination of amastigotes throughout the reticulendothelial system of the body
* Opportunistic infection in AIDS patients
* Ineffective humeral response
Hepatosplenomegaly
Splenic aspirate
* Most satisfactory method
* Spleen must be at least 3cm below LCM
* PT not more than 5 secs longer than controls
* Platelets >40,000
* 21 gauge needle
* Aspirate stained with Giemsa

Leishmaniasis: treatment
* Only drug approved in US is Amphotericin B
* Outside US: pentavalent antimony (sodium stibogluconate)
* Treatment of cutaneous disease depends on anatomic location
* Many spontaneously heal and do not require treatment
* If no mucosal disease and areas of no cosmetic concern:
o 15% paromomycin or 12% methylbenzethonium chloride
* Mucosal, progressive lesions or cosmetically sensitive locations:
o Pentavalent antimony or ketoconazole

Remember..
* The factors determining the form of leishmaniasis:
o Leishmanial species
o Geographic location
o Immune response of the host

Toxoplasmosis
Toxoplasma gondii
* Worldwide distribution
* Human infection
* Prevalence of latent infection in US about 10%; France about 75%
o Generally higher in less-developed world
Transmission
* Eating oocysts excreted by cats harboring sexual stages of parasite
* Outbreaks traced to inadequately cooked meat of herbivores (raw beef)
* Mutton
Toxoplasma gondii: life cycle
Immunocompetent hosts
* Latent infection (persistence of cysts) is generally asymptomatic
* Cervical lymphadenopathy (10-20%)
* Mono-like presentation (<1% of all mono-like illnesses) * Chorioretinitis * Very rare: myocarditis, myositis Toxoplasma gondii: Immunocompromised hosts * Often life-threatening * Almost always reactivation of latent infection * AIDS o Encephalitis most common manifestation o Usually subacute onset/focal (if CD4< 200) o Mental status changes, seizures, weakness, cranial nerve abnormalities, cerebellar signs, o Can present as acute hemiparesis/language deficit o Usually multiple ring-enhancing lesions on CT/MRI * Pneumonitis * Chorioretinitis Toxoplasma gondii: Clinical manifestations * Immunocompromised hosts o Non-AIDS (transplants, hematologic malignancies) * Congenital * Acute infection asymptomatic in mother * Clinical manifestations range: no sequelae to sequelae that develop at various times after birth o Chorioretinitis o Strabismus o Blindness o Epilepsy, mental retardation, pneumonitis, microcephaly, hydrocephalus, spontaneous abortion, stillbirth Toxoplasma gondii: diagnosis * Clinical suspicion crucial * Serology is primary method of diagnosis o IgM, IgG * Histopathology o Tachyzoites in tissue sections or body fluid (difficult to stain) o Multiple cysts near necrotic, inflammatory lesions Toxoplasma gondii: Treatment * Immunocompetent adults are usually not treated unless visceral disease is overt or symptoms are severe and persistent * Immunodeficient patients * Congenital: Ascaris lubricoides Ascaris lumbricoides * In GI tract, few symptoms in light infectionst. * Pulmonary: symptoms due to migration Effects of Adult Ascaris Worms * Depends on worm load * Effects * Toxic and Metabolic Ascaris lumbricoides Diagnosis * Characteristic eggs on direct smear examination * If treating mixed infections, treat Ascaris first o Mebendazole 100 mg bid x 3 days o Pyrantel 10 mg/kg single dose * Control: o Periodic mass treatment of children, health education, environmental sanitation Enterobius (Pinworm) * 18 million infections in U.S. * Incidence higher in whites * Preschool and elementary school most often * Mostly asymptomatic * Nocturnal anal pruritis cardinal feature due to migration and eggs * May have insomnia, possible emotional symptoms * DS-eggs or adults on perineum {scotch tape} * Mebendazole 100 mg. Repeat in 2 weeks. Pyrantel pamoate 11 mg/kg; repeat 2 weeks Strongyloides Strongyloides: Crucial Aspects of Life Cycle * Infection acquired through penetration of intact skin * Infection may persist for many years via autoinfection * In immunocompromised patients, there is risk of dissemination or hyperinfection o Hyperinfection syndrome Disseminated Strongyloidiasis * High mortality 75% * Penetration of gut wall by infective larvae * Gut organisms carried on the surface of larvae results in polymicrobial sepsis, meningitis * Larvae disseminate into all parts of body: CNS, lungs, bladder, peritoneum Summary—Clinical Findings * Defective cell-meditated immunity: steroids, burns, lymphomas, AIDS (?) * Gl symptoms in about two-thirds: o Abdominal pain o Bloating o Diarrhea o Constipation * Wheezing, SOB, hemoptysis Summary—Clinical Findings * Skin rash or pruritis in ~ one-third * Eosinophilia 60-95% * Less if on steroids Hookworm * Hookworm responsible for development of USPHS * Caused by two different species (North American and Old World) * Very similar to strongyloides in life cycle * Attaches to duodenum, feeds on blood * Elaborates anticoagulant, attaches and reattaches many times * Loss of around 0.1 ml/d of blood per worm Cutaneous larva migrans (creeping eruption) * Caused by filariform larvae of dog or cat hookworm (Ancylostoma braziliense or Ancylostoma duodenale * Common in Southeast U.S. * Red papule at entry with serpiginous tunnel * Intense pruritis * Self limiting condition * Diagnosis clinical * Topical or oral thiabendazole 25 mg/kg bid for 3-5 days * May use ethyl chloride topically * More common in children o Larvae penetrate skin and cause tingling followed by intense itching. * Eggs shed from dog and cat bowels develop into infectious larvae outside the body in places protected from desiccation and extremes of temperature * Shady, sandy areas under houses, at beach, etc. Usually not associated with systemic symptoms * Diagnosis and treatment * Skin lesions are readily recognized * Usually diagnosed clinically * Generally do not require biopsy # Reveal eosinophilia inflammatory infiltrate # Migrating parasite is generally not seen * Stool smear will reveal eggs Visceral Larva Migrans * Infection with dog or cat round worms * Toxocara canis; Toxocara catis * Underdiagnosed based on seroprevalence surveys * Heavy infections associated with fever, cough, nausea, vomiting, hepatomegaly, and eosinophilia * Uncommon in adults * Ocular type more common in adults * Diagnosis-ELISA * Thiabendazole: 25 mg/kg bid X 5 days Echinococcosis Hydatid Disease Echinococcosis * Clinical manifestations: o Most patients are asymptomatic + Dx’d incidentally on an imaging study o Sxs generally develop when the hydatid cyst reaches 8-10 cm (often over decades) + Compress vital structures + Erode into biliary tract or bronchus o Cysts can become superinfected o Leakage or rupture can result in anaphylactic reaction  fever, hypotension Echinococcosis * Diagnosis: o US, CT or MRI + Characteristic hydatid cyst with septated daughter cysts + May see head of the tapeworm o ELISA + Highly sensitive for liver cysts, less so for other organs Echinococcosis (Treatment) * Surgical resection of cyst * To reduce risk of spread: o Aspirate cyst o Instill hypertonic saline, iodophor, 95% ethanol to kill germinal layer and daughter cysts o No cidal agents in cases with biliary communication  risk of sclerosing cholangitis * Percutaneous aspiration-injection-reaspiration (PAIR) * Albendazole before and after surgery or PAIR Schistosomiasis Schistosomiasis: Epidemiology and life cycle Schistosomiasis: Clinical manifestations Schistosomiasis: Diagnosis and treatment * Detection of characteristic eggs in stool, urine or tissue biopsy is diagnostic o Urine is best between 12N and 2Pm, passed through 10 µm filter to concentrate eggs * Antibody tests are available, but limited by sensitivity, specificity * Praziquantel is the drug of choice S. mansoni Stool S. haematobium Urine S. japonicum African trypanosomiasis Trypanosoma brucei gambiense Blood smear Tsetse fly Treatment * Suramin * Melasoprol American trypanosomiasis Blood smear Reduviid bug (assassin bug) Chagas disease: Clinical manifestations Chagas disease: Diagnosis and treatment * Acute disease is diagnosed by seeing trypomastigotes on peripheral blood smear * Chronic disease is diagnosed by ELISA detecting IgG antibody to T. cruzi * Both acute and chronic disease can be treated with nifurtimox or benznidazole * Treatment slows the progression of heart disease Chagas Disease * Public health implications in the US * Chronic o Cardiomyopathy o Megaesophagus o Magacolon * Blood transfusion * Transplant o Solid organ o Musculoskeletal allograft tissue Tapeworms (Cestodes) * Adult worms inhabit GI tract of definitive vertebrate host * Larvae inhabit tissues of intermediate host * Humans o Definitive for T. saginata o Intermediate for Echinococcus granulosus (hydatid) o Both definitive and intermediate for T. solium * Adult worms shed egg-containing segments in stool ingested by intermediate host larval form in tissues Taenia saginata * Ingestion of raw or poorly cooked beef * Cows infected via the ingestion of human waste containing the eggs of the parasite * Cows contain viable cysticercus larvae in the muscle * Humans act as the host only to the adult tapeworms * Up to 25 meters in the lumen of intestine * Found all over the world, including the U.S. Beef Tapeworm Treatment * Praziquantel * Albendazole * Niclosamide Cystercercosis * Human infected with the larval stage of Taenia solium * Humans can serve as definitive or intermediate host * Eggs are ingested, or possibly get to stomach by reverse peristalsis * Probably much more common than is reported, since most infections are asymptomatic Cystercercosis * Symptoms depend on location of cysts, but frequently include motor spasms, seizures, confusion, irritability, and personality change * In the eye, often subretinal or in vitreous. Movement may be seen by the patient. Pain, amaurosis, and loss of vision may occur. * Clinical manifestations Cysticercosis * Diagnosis o CT and MRI preferred studies + Discrete cysts that may enhance + Usually multiple lesions # Single lesions especially common in cases from India + Older lesions may calcify o CSF + Lymphs or eos, low glucose, elevated protein o Serology + Especially in cases with multiple cysts Cysticercosis * Treatment o Complex and controversial o Praziquantel and albendazole may kill cysts, but death of larvae can increase inflammation, edema and exacerbate sxs o When possible, surgical resection of symptomatic cyst is preferred o Corticosteroids vs. edema and inflammation; antiseizure meds Babesiosis * Babesiosis caused by hemoprotozoan parasites of the genus Babesia * >100 species reported
* Few actually cause human infection
* Babesia microti
* Life cycle involves two hosts:
o Deer tick, Ixodes dammini, (definitive host) introduces sporozoites into white-footed mouse
* Once ingested by an appropriate tick gametes unite and undergo a sporogonic cycle resulting in sporozoites
* Humans enter cycle when bitten by infected ticks
Deer are the hosts upon which the adult ticks feed and are indirectly part of the Babesia cycle as they influence the tick population
* Clindamycin* plus quinine
* Atovaquone* plus azithromycin*
* Exchange transfusion in severely ill patients with high parasitemia

Classification of Parasitic Diseases
* Protozoa: amoeba; flagellates; ciliates; apicomplexa; microspors (primitive intracellular parasites)
* Metazoa (two phyla)
o Helminths (worms)
+ Nematodes
# Intestinal
# Extra-intestinal
+ Flatworms (platyhelminths)
# Cestodes (tapeworms)
# Trematodes (flukes)
o Arthopods (ectoparasites): scabies, lice, fly larvae

General rules of treatment
* Protozoa: require species-specific treatment
* Metozoa: species-specific

General rules of treatment of metazoa
Nematodes
Intestinal
Mebendazole or Albendazole
Tissue
Albendazole
Filiariae
Ivermectin, doxycycline
Cestodes
Praziquantel, Albendazole, Niclosamide
Trematode
Praziquantel
Ectoparasites
Permethrin, Ivermectin
This is just the beginning of a great adventure in infectious diseases
Sine qua non:history and physical examination

Emerging Infections and Medical Procedures.ppt

Read more...

25 March 2010

Chronic Pelvic Pain



Chronic Pelvic Pain
By:Jennifer Griffin, MD
M3 Student Clerkship Lecture
University of Nebraska Medical Center

Chronic Pelvic Pain
* Definition = Pain of apparent pelvic origin that has been present most of the time for 6 months
* Difficult to diagnose.
* Difficult to treat.
* Difficult to cure.
* =Physician and patient frustration.

Just because you’re a hammer doesn’t necessarily make every problem a nail.

Chronic Pelvic Pain
* Gynecologic
* Gastrointestinal
* Urologic
* Musculoskeletal/ Pelvic Floor
* Psychological
* United Kingdom data:
o Urinary dx 30.8%
o GI dx 37.7%
o Gynecologic 20.2%
o 25-50% have >1 dx
o MC Dx = endometriosis, adhesions, IBS, IC
Getting the History
* Nature of the Pain:
o Sharp, stabbing, colicky, burning?
o Where specifically is it located?
* Timing of the Pain:
o Does it come and go or is it constant?
o Does it occur with certain activities?
o Is it related to menses?
o Is it consistent and predictable?
* Modifying factors:
o Can you do anything to make it better/ worse?

Review of Systems
* Gynecologic:
o Association with menses?
o Association with sexual activity? (be specific)
o New sexual partners/ practices?
o Symptoms of vaginal dryness / atrophy?
o Other changes in menses?
o Use of contraceptives?
o Childbirth history and any associations?
o History of pelvic infections?
o History of other gyn problems/ surgeries?
* Gastrointestinal:
o Regularity of bowel movements?
o Diarrhea/ constipation/ flatus?
o Relief with defecation?
o History of hemorrhoids/ fissures/ polyps?
o Blood in stools, melena, or mucous?
o Nausea, vomiting, or appetite change?
o Weight loss?
* Urologic:
o Pain with urination?
o History of frequent / recurrent UTIs?
o Blood in urine?
o Symptoms of urgency or incontinence?
o Difficulty voiding?
* Musculoskeletal:
o History of trauma?
o Association with back pain?
o Other chronic pain problems?
o Association with position or activity?
* Psychological:
o History of abuse (verbal/ physical/ sexual)?
o Diagnosis of psychiatric disease?
o Association with life stressors?
o Exacerbated by life stressors?
o Family/ spousal support?
Chronic Pelvic Pain
* Diagnosis
o History and Physical
o Targeted imaging studies (U/S best for gyn evaluation)
o EMB/D&C
o Laparoscopy
o Cystoscopy/ Colonoscopy
o Physical therapy evaluation
* Gynecologic Origin
o Endometriosis
o Primary Dysmenorrhea
o Leiomyomas
o Dyspareunia
o Vaginismus
o Adenomyosis
o Infectious causes
o Pelvic congestion syndrome
o Pelvic organ immobility
o Cancer
* ACOG Practice

Gyn Causes
* Cyclic:
o Primary dysmenorrhea
o Endometriosis
o Adenomyosis
o Mittleschmertz
* Non-cyclic:
o Pelvic masses
o Adhesions
o Infections
o Non-gyn causes
* Related to intercourse:
o Endometriosis
o Vaginismus
o Vaginal atrophy
o Musculoskeletal
o Any non-cyclic cause could be exacerbated.

Chronic Pelvic Pain: Cyclic
* Endometriosis
Chronic Pelvic Pain: Cyclic
* Endometriosis: Etiology
* Endometriosis: Classic Triad
* But may present with:
o Chronic pelvic pain
o Adnexal mass
* Endometriosis: Diagnosis
* Endometriosis:
* Endometriosis: Treatment
* Dysmenorrhea
* Leiomyomas
* Adenomyosis
* Dyspareunia
* Vaginismus

Chronic Pelvic Pain: Dyspareunia
* Pelvic Floor Muscle Spasm and Strain
Chronic Pelvic Pain: Non-cyclic
* Pelvic congestion syndrome
* Pelvic organ immobility
* PID
* Infectious causes
* Gynecologic malignancies
* Other Gynecologic origin:
* Treatment of Gynecologic Problems
* Urologic Origin, Level A:
o Bladder malignancy
o Interstitial Cystitis
o Radiation Cystitis
o Urethral Syndrome
* Bladder origin, Level B:
* Urologic origin, Level C:
* Urologic origin
* Urologic origin: Interstitial Cystitis
* Gastrointestinal Origin, Level A:
* IBS
* Irritable Bowel Syndrome
* IBS Treatment
* Colon carcinoma
* Constipation
* Inflammatory Bowel Disease
* Gastrointestinal origin, Level C (no Level B):
* Musculoskeletal, Level A:
* Musculoskeletal origin, Level B:
* Musculoskeletal origin, Level C:
* Other Non-Gynecologic Origin, Level A:
* Psychological
* Other Non-Gynecologic origins, level B:
* Other Non-Gynecologic origin, Level C:
Clinical Pearl of Wisdom
Pelvic Pain Treatment Triad
* Medical treatment of most likely diagnosis.
* Psychiatric evaluation and treatment.
* Pelvic physical therapy.

Case Studies
Chronic Pelvic Pain
* Conclusions:
o Thorough history and physical
o Imaging and lab studies
o Many treatment options available

Chronic Pelvic Pain.ppt

Read more...

Pelvic Pain – Dysmenorrhea and Endometriosis



Pelvic Pain – Dysmenorrhea and Endometriosis

* A 20 y.o. woman presents to her gynecologist with a 4 year history of increasing lower abdominal pain with her menses. The pain begins on the first day of her menses and lasts 2-3 days. She also complains of lower back pain and nausea. Menarche occurred at the age of 13 and her menses occur every 28 days and last 5 days. Physical and pelvic exam are normal.

* How is dysmenorrhea diagnosed? How is it distinguished from other types of pelvic pain?
* What is the pathophysiology of dysmenorrhea?
* What are reasonable approaches to treatment?

Dysmenorrhea
* Dysmenorrhea – severe, painful cramping sensation in the lower abdomen often accompanied by other symptoms – sweating, tachycardia, headaches, n/v, diarrhea, tremulousness, all occurring just before or during menses
- Primary: no obvious pathologic condition, onset < 20 years old - Secondary: associated with pelvic conditions or pathology Primary Dysmenorrhea * Pathogenesis: elevated PG F2α in secretory endometrium (increased uterine contractility) * Treatment: NSAIDs – PG synthetase inhibitors – 1st line treatment of choice * Other treatment options: OCPs, other analgesics Secondary Dysmenorrhea * Etiologies - Cervical Stenosis - Endometriosis and Adenomyosis - Pelvic Infection - Adhesions - Pelvic Congestion - Stress and Tension * Cervical Stenosis - Severe narrowing of cervical canal may impede menstrual outflow – congenital or iatrogenic - can cause an increase in intrauterine pressure during menses - can lead to endometriosis * Cervical Stenosis - Hx – scant menstrual flow, severe cramping throughout menses - Dx – inability to pass a thin probe through the internal os OR HSG demonstrates thin cx canal - Tx – cervical dilation via D&C or laminaria placement * Pelvic Congestion - Due to engorgement of pelvic vasculature - Hx – burning or throbbing pain, worse at night and after standing - Dx – Laparoscopic visualization of engorgement/varicosities of broad ligament and pelvic sidewall veins Evaluation of Pelvic Pain * Detailed history, targeted physical exam, labs (UA, UCx, CBC, HCG, tumor markers), diagnostic imaging studies (US, MRI, CT) as appropriate * Consider age of patient * “OLDCAAR”: onset, location, duration, context, associated sx, aggravating/relieving factors * Temporal characteristics: cyclic (e.g. dysmenorrhea), intermittent (e.g. dyspareunia), non-cyclic * Risk factors * GYN and Non-GYN causes DDx Pelvic Pain - GYN * GYN - Uterus - fibroids, adenomyosis, endometritis - Fallopian tubes - PID/salpingitis, hydrosalpinx, ectopic - Ovaries - cysts – functional, pathological, TOA, torsion; mittleschmerz - Other - endometriosis, adhesions, IUD/infection, severe prolapse DDx Pelvic Pain – Non-GYN * Urologic - UTI/urethritis, interstitial cystitis (IC), OAB, urethral diverticulum, nephrolithiasis, malignancy * GI - constipation, IBS, IBD (Crohn’s, UC), bowel obstruction, diverticulitis, malignancy, appendicitis * Musculoskeletal - trigger points, fibromyalgia, hernias, neuralgia, low back pain * Other - psychiatric – depression, somatization; abdominal cutaneous nerve entrapment in surgical scar; celiac disease Case 1 * At the age of 30, the patient presents with a 2 year history of infertility. Her menses are still regular but she has 2-3 days of spotting before her menses are due. She also complains of pain with intercourse and pelvic pain. In reviewing the patient’s history, the gynecologist notes that over the past year the patient was repeatedly treated by her internist with antibiotics for recurrent microscopic hematuria. * What is the most likely diagnosis? * What are the main theories regarding the pathogenesis in this case? * How would you evaluate and treat this patient? Endometriosis - Symptoms * Variable and unpredictable - asymptomatic - dysmenorrhea - CPP - deep dyspareunia - sacral backache w/ menses - dysuria +/- hematuria (bladder involvement) - dyschezia/hematochezia (bowel involvement) Endometriosis – Physical Exam * Uterosacral nodularity * Adnexal mass (endometrioma) * Normal exam Endometriosis - Incidence * 7-10% of general population * 20-50% of infertile women * 70-85% in women w/ CPP * No racial predisposition * +Familial association with almost 10x increased risk of endometriosis if affected 1st degree relative Endometriosis - Pathogenesis * Retrograde menstruation (Sampson) * Hematogenous or lymphatic spread (Halban) * Coelomic metaplasia (Meyer/Novack) * Iatrogenic dissemination * Immunologic defects (Dmowski) * Genetic predisposition Endometriosis - Pathogenesis * Retrograde menstruation (Sampson’s theory) - Monkey experiments – sutured cervix closed to create outflow obstruction caused development of endometriosis - Clinical observation of retrograde menstrual flow during laparoscopy in humans - Increased risk of endometriosis in women with cervical/vaginal atresia, other outflow obstruction - Increased risk with early menarche, longer and heavier flow - Decreased risk with decreased estrogen levels e.g. exercise-induced menstrual disorders, decreased body fat, + tobacco use Endometriosis - Pathogenesis * Hematogenous or lymphatic spread - Endometriosis found in remote sites – lung, nose, spinal cord, pelvic lymph nodes. Endometriosis - Pathogenesis * Coelomic metaplasia - Mullerian ducts are derived from coelomic epithelium during fetal development - Hypothesize that coelomic epithelium retains ability for multipotential development - Endometriosis seen in prepubertal girls, women w/ congenital absence of the uterus, and RARELY in men Endometriosis - Pathogenesis * Iatrogenic dissemination - Endometriosis has been found in cesarean section scar * Immunologic defects * Genetic predisposition - polygenic, multi-factorial Endometriosis - Diagnosis * Laparoscopy with biopsy proven histologic diagnosis – standard for dx of endometriosis * Empiric medical treatment with improvement in symptoms * CA 125 – NOT considered to be of clinical utility * Imaging – US, MRI, CT – only useful in the presence of pelvic or adnexal masses (endometriomas) * Laparoscopy with biopsy proven histologic diagnosis – standard for dx of endometriosis - Extent of visible lesions do not correlate with severity of sx, but depth of infiltration of lesions seems to correlate best with pain severity - classic powder-burn lesions, endometriomas - lesions can be red, clear or white – more commonly seen in adolescents * Endometrial epithelium * Endometrial glands * Endometrial stroma * Hemosiderin-laden macrophages 2 or more of the following histologic features are criteria for Dx: * Imaging – US, MRI, CT – only useful in the presence of pelvic or adnexal masses (endometriomas) - on US, endometriomas appear as cysts that contain low-level homogeneous internal echoes consistent with old blood (ddx includes hemorrhagic cysts) Endometriosis - Treatment * Medications - Progestins - OCPs – continuous vs. cyclic – if no relief in 3 months, consider tx with Depo Provera or GnRH agonist - NSAIDs - GnRH agonists – most expensive - Danazol – appears to be as effective as GnRH agonist for pain relief but with increased side-effects * GnRH agonists – create a state of relative estrogen deficiency – vasomotor side effects and potential decrease in bone density - 12-month course of GnRH agonist therapy associated with 6% decrease in bone density - No data regarding extended treatment with GnRH agonists beyond 1 year * Add-back therapy is advocated for women undergoing long-term therapy (i.e. > 6 months)
* Some evidence to suggest that immediate add-back therapy may result in even less bone loss
- Add-back regimens: progestins alone, progestins + bisphosphonates, low-dose progestins + estrogens, pulsatile PTH

Endometriosis – Treatment Considerations in Adolescents
* GnRH treatment is NOT recommended for patients < 18 years because the effects of these medications on bone formation and long-term bone density have not been adequately studied * Depo provera used for longer than 2 years has been shown to decrease bone density in adolescents – FDA warning against long-term use * If no improvement in symptoms after 3 months of empiric treatment with NSAIDs and OCPs, diagnostic laparoscopy should be offered Endometriosis - Treatment * Surgery - Laparoscopic laser vaporization vs. cauterization vs. excision - Ovarian cystectomy for endometrioma - Hysterectomy +/- BSO * Medications vs. Surgery - Lack of data to support surgery vs. medical treatment for tx of pain symptoms due to endometriosis - Starting with empiric medical therapy is appropriate - Offer GnRH agonist therapy if initial medical treatment with OCPs and NSAIDs not helping - Cost of comparing empiric medical management with definitive surgical diagnosis is difficult to assess, but 3 months of empiric treatment is less than a laparoscopic procedure .... Pelvic Pain – Dysmenorrhea and Endometriosis.ppt

Read more...

Urinary Tract Infections



Urinary Tract Infections
By:Lourdes Lozano Vargas

Urinary Tract Infections
* Leading cause of morbidity and health care expenditures in persons of all ages.
* An estimated 50 % of women report having had a UTI at some point in their lives.
* 8.3 million office visits and more than 1 million hospitalizations, for an overall annual cost > $1 billion.

Acute Uncomplicated Cystitis
* Sexually active young women.
* Causes: anatomy and certain behavioral factors, including delays in micturition, sexual activity, and the use of diaphragms and spermicides tract.
* Aggressive diagnostic work-ups are unwarranted in young women presenting with an uncomplicated episode of cystitis.

Acute Uncomplicated Cystitis
* The microbiology is limited to a few pathogens.
* 70%- 85% are caused by Escherichia coli
* 5-20%are caused by coagulase-negative Staphylococcus saprophyticus
* 5-12% are caused by other Enterobacteriaceae such as Klebsiella and Proteus.

Acute Uncomplicated Cystitis
* Clinical Features: dysuria, frequency, urgency, suprapubic pain, hematuria.
o Fever >38C, flank pain, costovertebral angle tenderness, and nausea or vomiting suggest upper tract infection.

Acute Uncomplicated Cystitis
* Diagnosis: direct history and PE
* PE: Temperature, abdominal exam, assessment of CVA tenderness, pelvic exam.
o H/o STD’s, new sexual partner, partner with urethral symptoms, gradual onset.

Acute Uncomplicated Cystitis
* Guidelines for tx of acute cystitis recommend empiric antibiotic tx.
* Unnecessary antibiotic use??
* Clinical criteria for Dx:

Dysuria, presence of > trace urine leukocytes, and presence of nitrites or...
Dysuria and frequency in the absence of vaginal discharge.
Acute Uncomplicated Cystitis
* UA: Evaluation of midstream urine for pyuria.
o White blood cell casts in the urine are Dx of upper tract infection.
* Urine Culture: Not necessary
o Warranted in: Suspected complicated infection, persistent symptoms following tx, symptoms recur < 1 mo after tx. Acute Uncomplicated Cystitis * Urine dipsticks: o Leukocyte esterase (pyuria), sensitivity 75-90%, specificity 95% o Nitrite (Enterobacteriacea), sensitivity 35-85%, specificity 95%, false positive with phenazopyridine, beets. o Microscopic evaluation for pyuria or a culture is indicated in pt with negative leukocyte esterase that have urinary symptoms. Acute Uncomplicated Cystitis * Susceptibility: o E.coli o S.saprophyticus Acute Uncomplicated Cystitis * Treatment: o Short course vs. prolonged tx + Short course preferred except with beta-lactam agents o TMP-SMX (160/800mg BID x 3) first-line tx if: no allergy to the drug, no antibiotics in the past 3 mo, no recent hospitalization. o Nitrofurantoin (100mg BID x 5 days) o Analgesia: Phenazopyridine 200mg TIDx2 Acute Urethral Syndrome * Acute symptomatic women with dysuria and frequency with a midstream culture containing < 10(5) CFU/mL. * > 10(2) CFU/mL in women with acute symptomatic pyuria = UTI
* Tx as an uncomplicated UTI
* Mycoplasma genitalium, Ureaplasma urealyticum

Acute Complicated Cystitis
* UTI when/with structural, functional or metabolic abnormalities (polycystic, solitary, transplant kidney;DM, CRF, indwelling cath, neurogenic bladder) or elderly, male, child, pregnant or h/o recurrent UTI)
* E.coli accounts for fewer than one third of complicated cases.
* Clinically, the spectrum of complicated UTIs may range from cystitis to urosepsis with septic shock.

Acute Complicated Cystitis
* Urine culture and susceptibility are necessary.
* These infections are usually associated with high-count bacteriuria (> 10(5) CFU/mL).
* MO: Proteus, Klebsiella, Pseudomonas, Serratia, and Providencia, enterococci, staphylococci and fungi AND E.coli

Acute Complicated Cystitis
* Empiric therapy for these patients should include an agent with a broad spectrum of activity against the expected uropathogens: fluoroquinolone, ceftazidime, cefepime, aztreonam, imipenem-cilastatin. (Obtain Ucx prior to Tx)
* Tx x 7-14 days
* Follow-up urine culture should be performed within 14 days after treatment???

Recurrent Cystitis
* Up to 27% of young women with acute cystitis develop recurrent UTIs.
* The causative organism should be identified by urine culture.
* Relapse: infection with the same organism (multiple relapses = complicated UTIs).
* Recurrence: infection with different organisms.

Recurrent Cystitis
* >3 UTI recurrences documented by urine Cx within one year can be managed using one of three preventive strategies:
* Acute self-treatment with a three-day course of standard therapy.
* Postcoital prophylaxis with one-half of a TMP-SMX double-strength tablet (80/400 mg).
* Continuous daily prophylaxis TMP-SMX one-half tablet per day (40/200 mg); nitrofurantoin 50 to 100 mg per day; norfloxacin 200 mg per day.

Uncomplicated Pyelonephritis
* Suspect if:
o Cystitis-like illness and accompanying flank pain
o Severe illness with fever, chills, nausea, vomiting, abdominal pain
o Gram-negative bacteremia.

Uncomplicated Pyelonephritis
* DX: Clinical, confirm with:
o UA: pyuria and/or WBC casts
o UCx with > 10 (5) CFU/mL (80%)
* Tx: 14 days total
o Oral: TMP/SMX, fluoroquinolones
o IV: 3rd gen cephalosporin, aztreonam, quinolones, aminoglycoside

Uncomplicated Pyelonephritis
* Pt with symptoms after 3 days of appropriate antimicrobial tx should be evaluated by renal US or CT for obstruction or abscess.

UTI in Men

* At risk: Older men with prostatic disease, UT instrumentation, anal sex, or partner colonized with uropathogens.
* UCx: 10 (3) CFU/mL sensitivity and specificity 97%.
* Additional studies?
o Not necessary in young healthy men who have a single episode.

UTI in Men
* Tx:
o Uncomplicated cystitis:
+ TMP/SMX or fluoroquinolones x 7 days
o Complicated cystitis:
+ Fluoroquinolones x 7-14 days
o Bacterial prostatitis:
+ Fluoroquinolone x 6-12 weeks

Catheter-Associated UTI
* Risk of bacteriuria is ~ 5%/day (long term catheter bacteriuria is inevitable).
* 40% of nosocomial infections
* Most common source of gram-negative bacteremia.
* Dx: Ucx 10 (2) CFU/mL
o MO: E.coli, Proteus, Enterococcus, Pseudomona, Enterobacter, Serratia, Candida

Catheter-Associated UTI
* Mild to mod: oral quinolones10-14days
* Severe infection: IV/oral 14-21days
* Asymptomatic bacteriuria in pt with an indwelling Foley should not be Tx unless they are immunosuppressed, have risk of bacterial endocarditis or pt who are about to undergo urinary tract instrumentation.

Asymptomatic Bacteriuria
* UCx: > 10(5)CFU/mL with no symptoms
* Three groups of pt with asymptomatic bacteruria have been shown to benefit from tx:
o Pregnant
o Renal transplant
o Pt who are about to undergo urinary tract procedures.

Pregnant patients

* Asymptomatic bacteriuria: two consecutive voided urine specimens with isolation of the same bacterial strain >10(5) or a single cath urine specimen.
o Nitrofurantoin 100mg BID x 5-7 days
o Amoxi/Clav 500mg BID or 250 TID x 7days
o Fosfomycin 3g PO x 1

Interstitial Cystitis
* Frequency, urgency, urge incontinence with periurethral and suprapubic pain on bladder filling that is improved by voiding. Terminal hematuria may be present.
* Etiology. Unclear (autoimmune, altered glycosaminoglycal layer, allergic)

Interstitial Cystitis
* TX
o Refer to urology for cystoscopy.
o Dietary modifications
o Behavioral modifications
o Rx:
+ Pyridium
+ Pentosan polysulfate 100mg TID x 6mo to 2 years.
+ Amitriptyline 10-75mg QHS

Interstitial Cystitis
* Intravesical therapies
o Dimethyl Sulfoxide instillations q1-2 wks
o BCG instilled q1wk x 6-8 wks
o Hyaluronic acid instilled q1wk x 4-6wk.

References

Urinary Tract Infections.ppt

Read more...

Oral Cavity



Oral Cavity
By:Robert Scranton© 2008

The Tissues
Lining Mucosa
Masticatory Mucosa
* NKSS (nonkeratinized stratified squamous)
* Lamina Propria- loose CT w/ collagen bundles
o Mucous and serous glands
o Fordyce Spots
* Location?
* KSS/PKSS (keratinized/parakeratinized stratified squamous)
* Variable Lamina Propria
* Location?

Lining Mucosa
Don’t forget the soft palate
Diagrams are important

Identify:
* vermillion zone
* Hair follicle
* Epithelium, what type?
* Skeletal muscle
o what is the name?

Special Mucosa
* Filiform
o Most abundant
o Dorsal surface
* Fungiform
o Occasional tasebuds, CN-VII
* Vallate
o 8-12 along sulcus terminalis
o Crypt
o Serous glands of Von Ebner
o CN- IX, taste buds
* Foliate
o Dorsolateral surfaces, taste buds?

Identify filiform and fungiform
Vallate/ circumvallate

Teeth
* We origionally have __ baby (________) teeth. Adults have ___ teeth.
* What are the three cell types that form the teeth and what parts do they form?
* What do dentin and enamel have in common?
* Which is acellular?

Mesenchymal CT pulp cavity
Odontoblasts (mesenchyme) Dentin
ameloblasts (ectoderm) Enamel
Avascular
Ca2+ Hydroxyapatite (calcified organic Matrix
Enamel
Teeth
* The little tubules in the teeth, what is their story?
* Damage to What three things can lead to loss of a tooth?
* Dentinal tubules- the tubule that the cytoplasmic process of odontoblasts extend through for nociception
* Canaliculi- the tubules that cementocytes use to maintain cementum
* Bony Socket
* Peridontal ligament
* Cementum

Identify:
* Alveolar Bone
* Free Gingiva
* Attached Gingiva
* Alveolar Mucosa
* Gingival Ligament
* Gingival Sulcus
* Alveolar Bone
* Dentin
* Peridontal ligament
* Pulp Cavity
* Gingiva
* Odontoblasts
* Predentin
* Dentin
* Cementocytes
* Peridontal Ligament

Salivary Glands
Intrinsic
Extrinsic
* AKA minor
* Serous
* Mucous
* Mixed
* Means w/in lamina propria
* AKA Major
* Serous
* Serousmucous
* Outside oral cavity
* Has large ducts

Important words
* Serous amylase
* Serous demilunes bacteriolytic lysozyme
* IgA bacteriostatic, resistant to degradation
* Nasopharynx Respiratory Epithelium
* Oropharynx lining mucosa, NKSS
* Laryngopharynx transitional zone so KSS, NKSS

Oral Cavity.ppt

Read more...

Chemical composition and functions of saliva



Chemical composition and functions of saliva
By:Dennis E. Lopatin, Ph.D.

Chronology of defining salivary components and functions
* Beginning in 1950’s whole saliva evaluated (antimicrobial properties, role in microbial attachment, mineralization, taste, lubrication)
* Secretions of major glands (parotid and submandibular/sublingual)
* In 1970’s individual components isolated and biochemically characterized
* In mid-1980’s beginning to map functional domains (peptide synthesis and recombinant approaches)

Major salivary components
Mucin 1 (MG1)
sIgA
Mucin 2 (MG2)
Lactoferrin
Peroxidases
Amylases
Carbonic anhydrases
Proline-rich proteins
Lysozyme
Statherins
Histatins

Current concepts regarding the functional features of salivary macromolecules
* Recent structure/function studies have identified general principles regarding function
* Based on in vitro studies of purified molecules
* Additional studies required to evaluate concepts in situ

Conformational requirements
* Conformation or shape of a molecule is critical for its biological function
* Examples
o Proline-rich proteins interact with A. viscosus and St. gordonii only when adsorbed onto mineralized surface
o Statherins and histatins require -helical conformation
o Human salivary amylase require 5 inter-chain disulfide bonds

Multifunctionality
Salivary
Families
Anti-Bacterial
Buffering
Digestion
Mineralization
Lubrication &Viscoelasticity
Tissue
Coating
Anti-Fungal
Anti-Viral
Carbonic anhydrases,
Histatins
Amylases,
Mucins, Lipase
Cystatins,
Histatins, Proline rich proteins,
Statherins
Mucins, Statherins
Amylases,
Cystatins, Mucins,
Proline-rich proteins, Statherins
Histatins
Cystatins,
Mucins
Amylases, Cystatins,
Histatins, Mucins,
Peroxidases
Redundancy
* Saliva has built-in redundancy in regard to its protective functions.
* Example - Many salivary molecules can inhibit the precipitation of calcium phosphate salts.
o strong inhibitors such as statherin and acidic proline-rich proteins
o moderate inhibitors such as histatins and cystatins
o weak inhibitors such as mucins and amylase

Amphifunctionality
* A molecule may have both protective and detrimental properties - “double-edged sword”.
* May depend on molecule’s location or site of action
o Amylases
+ In solution, they facilitate clearance of viridans streptococci
+ Adsorbed to tooth surface, they can promote adherence of these bacteria and digest starch to dietary maltose and production of acid
o Statherin and acidic proline-rich proteins
+ At enamel surface, they play an important role in mineralization by inhibiting the formation of primary and secondary calcium phosphate salts. When adsorbed to the enamel surface, they promote attachment of cariogenic microorganisms.

Complexing
* Functional relationships exist between different molecules in saliva
* Two types of complexing (covalent and non-covalent)
o homotypic (between similar molecules)
o heterotypic (between different molecules)
* Example: Mucins
o homotypic complexes necessary for lubrication and viscoelastic properties
o heterotypic complexes with sIgA, lysozyme and cystatins concentrate these anti-microbials at tissue interfaces
Salivary Protein Functions
Mucins
* Lack precise folded structure of globular proteins
* Asymmetrical molecules with open, randomly organized structure
* Polypeptide backbone (apomucin) with CHO side-chains
* Side-chains may end in negatively charged groups, such as sialic acid and bound sulfate
* Hydrophillic, entraining water (resists dehydration)
* Unique rheological properties (e.g., high elasticity, adhesiveness, and low solubility)
* Two major mucins (MG1 and MG2)

Mucin Functions
* Tissue Coating
o Protective coating about hard and soft tissues
o Primary role in formation of acquired pellicle
o Concentrates anti-microbial molecules at mucosal interface
* Lubrication
o Align themselves with direction of flow (characteristic of asymmetric molecules)
o Increases lubricating qualities (film strength)
o Film strength determines how effectively opposed moving surfaces are kept apart
* Aggregation of bacterial cells
o Bacterial adhere to mucins may result in surface attachment, or
o Mucin-coated bacteria may be unable to attach to surface
* Bacterial adhesion
o Mucin oligosaccharides mimic those on mucosal cell surface
o React with bacterial adhesins, thereby blocking them

Amylases
* Calcium metalloenzyme
* Hydrolyzes (1-4) bonds of starches such as amylose and amylopectin
* Several salivary isoenzymes
* Maltose is the major end-product (20% is glucose)
* “Appears” to have digestive function
* Why is it also present in tears, serum, bronchial, and male and female urogenital secretions?
* A role in modulating bacterial adherence?

Lingual Lipase
* Secreted by von Ebner’s glands of tongue
* Involved in first phase of fat digestion
* Hydrolyzes medium- to long-chain triglycerides
* Important in digestion of milk fat in new-born
* Unlike other mammalian lipases, it is highly hydrophobic and readily enters fat globules

Statherins
* Calcium phosphate salts of dental enamel are soluble under typical conditions of pH and ionic strength
* Supersaturation of calcium phosphates maintain enamel integrity
* Statherins prevent precipitation or crystallization of supersaturated calcium phosphate in ductal saliva and oral fluid
* Produced by acinar cells in salivary glands
* Also an effective lubricant

Proline-rich Proteins (PRPs)
* Like statherin, PRPs are also highly asymmetrical
* Inhibitors of calcium phosphate crystal growth
* Inhibition due to first 30 residues of negatively-charged amino-terminal end
* Present in the initially formed enamel pellicle and in “mature” pellicles

Role of PRPs in enamel pellicle formation
* Acquired enamel pellicle is 0.1-1.0 µm thick layer of macromolecular material on the dental mineral surface
* Pellicle is formed by selective adsorption of hydroxyapatite-reactive salivary proteins, serum proteins and microbial products such as glucans and glucosyl-transferase
* Pellicle acts as a diffusion barrier, slowing both attacks by bacterial acids and loss of dissolved calcium and phosphate ions

Remineralization of enamel and calcium phosphate inhibitors
* Early caries are repaired despite presence of mineralization inhibitors in saliva
* Sound surface layer of early carious lesion forms impermeable barrier to diffusion of high mol.wt. inhibitors.
* Still permeable to calcium and phosphate ions
* Inhibitors may encourage mineralization by preventing crystal growth on the surface of lesion by keeping pores open

Calculus formation and calcium phosphate inhibitors
* Calculus forms in plaque despite inhibitory action of statherin and PRPs in saliva
* May be due to failure to diffuse into calcifying plaque
* Proteolytic enzymes of oral bacteria or lysed leukocytes may destroy inhibitory proteins
* Plaque bacteria may produce their own inhibitors

Calcium phosphate precipitation inhibitors and plaque
* Statherin and PRPs might be expected to occur in plaque, have not been detected
* Plaque bacteria produce calcium phosphate inhibitors
* Might be necessary to prevent calcification of bacteria -- happens with dead cells
* Immobilized crystal growth inhibitors can function as nucleators of crystal growth
* Immobilization may occur in plaque, encouraging calculus formation

Interaction of oral bacteria with PRPs and other pellicle proteins
* Several salivary proteins appear to be involved in preventing or promoting bacterial adhesion to oral soft and hard tissues
* PRPs are strong promoters of bacterial adhesion
o Amino terminal: control calcium phosphate chemistry
o Carboxy terminal: interaction with oral bacteria
* Interactions are highly specific
o Depends on proline-glutamine carboxy-terminal dipeptide
o PRPs in solution do not inhibit adhesion of bacteria

These anti-microbial proteins will be discussed in a later lecture
* Secretory Immunoglobulins
* Lactoferrin
* Lysozyme
* Sialoperoxidase
* Cystatins
* Histatins

Summary - Clinical Highlights
* Understanding of salivary mechanisms at fundamental level a prerequisite for
o effective treatment of salivary gland dysfunctions
o modulation of bacterial colonization
o development of artificial saliva other “cutting edge” approaches to salivary dysfunctions and diseases

Chemical composition and functions of saliva.ppt

Read more...

Salivary Glands



Salivary Glands

Major glands
* Parotid: so-called watery serous saliva rich in amylase, proline-rich proteins
o Stenson’s duct
* Submandibular gland: more mucinous
o Wharton’s duct
* Sublingual: viscous saliva
o ducts of Rivinus; duct of Bartholin

Minor glands
* Minor salivary glands are not found within gingiva and anterior part of the hard palate
* Serous minor glands=von Ebner below the sulci of the circumvallate and folliate papillae of the tongue
* Glands of Blandin-Nuhn: ventral tongue
* Palatine, glossopalatine glands are pure mucus
* Weber glands

Functions
* Protection
o lubricant (glycoprotein)
o barrier against noxious stimuli; microbial toxins and minor traumas
o washing non-adherent and acellular debris
o formation of salivary pellicle
+ calcium-binding proteins: tooth protection; plaque
* Buffering (phosphate ions and bicarbonate)
o bacteria require specific pH conditions
o plaque microorganisms produce acids from sugars

Functions

* Digestion
o neutralizes esophageal contents
o dilutes gastric chyme
o forms food bolus
o brakes starch
* Antimicrobial
o lysozyme hydrolyzes cell walls of some bacteria
o lactoferrin binds free iron and deprives bacteria of this essential element
o IgA agglutinates microorganisms
* Maintenance of tooth integrity
o calcium and phosphate ions
+ ionic exchange with tooth surface
* Tissue repair
o bleeding time of oral tissues shorter than other tissues
o resulting clot less solid than normal
o remineralization
* Taste
o solubilizing of food substances that can be sensed by receptors
o trophic effect on receptors

Embryonic development
* The parotid: ectoderm (4-6 weeks of embryonic life)
* The sublingual-submandibular glands: endoderm
* The submandibular gland around the 6th week
* The sublingual and the minor glands develop around the 8-12 week
* Differentiation of the ectomesenchyme
* Development of fibrous capsule
* Formation of septa that divide the gland into lobes and lobules

Serous cells
* Seromucus cells=secrete also polysaccharides
* They have all the features of a cell specialized for the synthesis, storage, and secretion of protein
o Rough endoplasmic reticulum (ribosomal sites-->cisternae)
o Prominent Golgi-->carbohydrate moieties are added
Secretory granules-->exocytosis
* The secretory process is continuous but cyclic
* There are complex foldings of cytoplasmic membrane
* The junctional complex consists of:
o Tight junctions (zonula occludens)-->fusion of outer cell layer
o Intermediate junction (zonula adherens)-->intercellular communication
o Desmosomes-->firm adhesion

Mucous cells
* Production, storage, and secretion of proteinaceous material; smaller enzymatic component
-more carbohydrates-->mucins=more prominent Golgi
-less prominent (conspicuous) rough endoplasmic reticulum, mitochondria
-less interdigitations

Formation and Secretion of Saliva
* Primary saliva
o Serous and mucous cells
o Intercalated ducts
* Modified saliva
o Striated and terminal ducts
o End product is hypotonic

Macromolecular component
* Synthesis of proteins
* RER, Golgi apparatus
* Ribosomes RER posttranslational modification (N- & O-linked glycosylation) Golgi apparatus Secretory granules
* Exocytosis
* Endocytosis of the granule membrane

Fluid and Electrolytes
* Parasympathetic innervation
* Binding of acetylcholine to muscarinic receptors
o Activation of phospholipase IP3 release of Ca2+ opening of channels K+, Cl- Na+ in
o K+ and Cl- in
o Also another electrolyte transport mechanism through HCO3-
* Noepinephrine via alpha-adrenergic receptors
o Substance P activates the Ca2+

Myoepithelial cells
* One, two or even three myoepithelial cells in each salivary and piece body
* Four to eight processes
* Desmosomes between myoepithelial cells and secretory cells
* Myofilaments frequently aggregated to form dark bodies along the course of the process

Myoepithelial cells
* The myoepithelial cells of the intercalated ducts are more spindled-shaped and fewer processes
* Ultrastructurally very similar to that of smooth muscle cells
* Functions of myoepithelial cells
o Support secretory cells
o Contract and widen the diameter of the intercalated ducts
o Contraction may aid in the rupture of acinar cells of epithelial origin

Intercalated Ducts
* Small diameter
* Lined by small cuboidal cells
* Nucleus located in the center
* Well-developed RER, Golgi apparatus, occasionally secretory granules, few microvilli
* Myoepithelial cells are also present
* Intercalated ducts are prominent in salivary glands having a watery secretion (parotid).

Striated Ducts
* Columnar cells
* Centrally located nucleus
* Eosinophilic cytoplasm
* Prominenty striations
o Indentations of the cytoplasmic membrane with many mitochondria present between the folds
* Some RER and some Golgi, short microvilli
* Modify the secretion
o Hypotonic solution=low sodium and chloride and high potassium
* Basal cells

Terminal excretory ducts
* Near the striated ducts they have the same histology as the striated ducts
* As the duct reaches the oral mucosa the lining becomes stratified
* Goblet cells, basal cells, clear cells.
* Alter the electrolyte concentration and add mucoid substance.

Ductal modification
* Autonomic nervous system
* Striated and terminal ducts
* Modofication via reabsorption and secretion of electrolytes
* Final product is hypotonic
* Rate of salivary flow
o High: Sodium and chlorine up; potassium down

Connective tissue
* Fibroblasts
* Inflammatory cells
* Mast cells
* Adipose cells
* Extracellular matrix
o Glycoproteins and proteoglycans
* Collagen and oxytalan fibers
* Blood supply

Nerve supply
* No direct inhibitory innervation
* Parasympathetic and sympathetic impulses
* Parasympathetic are more prevalent.
* Parasympathetic impulses may occur in isolation, evoke most of the fluid to be excreted, cause exocytosis, induce contraction of myoepithelial cells (sympathetic too) and cause vasodilatation.
* There are two types of innervation: Epilemmal and hypolemmal
* beta-adrenergic receptors that induce protein secretion
* L-adrenergic and cholinergic receptors that induce water and electrolyte secretion

Hormones can influence the function of the salivary glands. They modify the salivary content but cannot iniate salivary flow.

Age changes
* Fibrosis and fatty degenerative changes
* Presence of oncocytes (eosinophilic cells containing many mitochondria)

Clinical Considerations
* Obstruction
* Role of drugs
* Systemic disorders
* Bacterial or viral infections
* Therapeutic radiation
* Formation of plaque and calculus

Salivary Glands.ppt

Read more...

24 March 2010

Examination of Urine



Examination of Urine
By:Terry Kotrla, MS, MT(ASCP)
Professor
Austin Community College


Urine Color

* Normal urine color ranges from pale yellow to deep amber — the result of a pigment called urochrome
o B vitamins turn urine an eye-popping neon yellow BUT may also indicate liver disease.
o porphyria, a disease that affects your skin and nervous system, turns urine the color of port wine.

Urine Color

* Most changes in urine color are harmless and temporary and may be due to:
o Certain foods – beets may turn urine red
o Dyes in foods/drinks
o Supplements – vitamins
o Prescription drugs
* Unusual urine color can indicate an infection or serious illness .

Suggested Colors

* pale yellow (straw)
* light yellow
* yellow
* green-yellow (olive)
* red-yellow
* red
* red-brown
* brown-black
* black
* milky

Examples of Urine Color

Urine Clarity

* During the visual inspection, the MLT observes the urine's and determines how clear it is (its clarity).
* Urine clarity refers to how clear the urine is.
* Terms used: clear, slightly cloudy, cloudy, or turbid.
* “Normal” urine can be clear or cloudy.
* The clarity of the urine is not as important as the substance that is causing the urine to be cloudy.

Urine Clarity

* Substances that cause cloudiness but that are not considered unhealthy include:
o mucous,
o sperm and prostatic fluid,
o cells from the skin,
o normal urine crystals, and
o contaminants (like body lotions and powders).
* Other substances that can make urine cloudy (such as red blood cells, white blood cells, or bacteria) indicate a condition that requires attention.

Examples of Urine Clarity

Urine Color and Clarity

* Urine color and clarity can indicate what substances may be present in urine.
* Confirmation of suspected substances is obtained during the chemical and microsopic examination.

Chemical Examination

* Reagent strips are used only once and discarded.
* Testing
o Perform within 1 hour after collection
o Allow refrigerated specimens to return to room temperature.
o Dip strip in fresh urine and compare color of pads to the color chart after appropriate time period.
o Instruments are available which detect color changes electronically

Using Reagent Strips

* BRIEFLY dip the strip in urine.
* Colors are matched to those on the bottle label at the appropriate times.
* Timing is critical for accurate results.

Reagent Strips

Glucose

* Presence of glucose (glycosuria) indicates that the blood glucose level has exceeded the renal threshold.
* Useful to screen for diabetes.

Bilirubin

* Bilirubin is a byproduct of the breakdown of hemoglobin.
* Normally contains no bilirubin.
* Presence may be an indication of liver disease, bile duct obstruction or hepatitis.
* Since the bilirubin in samples is sensitive to light, exposure of the urine samples to light for a long period of time may result in a false negative test result.

Ketones

* Ketones are excreted when the body metabolizes fats incompletely (ketonuria)

Specific Gravity

* Specific gravity reflects kidney's ability to concentrate.
* Want concentrated urine for accurate testing, best is first morning sample.
* Low – specimen not concentrated, kidney disease.
* High – first morning, certain drugs

Blood

* Presence of blood may indicate infection, trauma to the urinary tract or bleeding in the kidneys.
* False positive readings most often due to contamination with menstrual blood.

Ph

* pH measures degree of acidity or alkalinity of urine

Protein

* Presence of protein (proteinuria) is an important indicator of renal disease.
* False negatives can occur in alkaline or dilute urine or when primary protein is not albumin.

Urobilinogen

* Urobilinogen is a degradation product of bilirubin formed by intestinal bacteria.
* It may be increased in hepatic disease or hemolytic disease

Nitrite

* Nitrite formed by gram negative bacteria converting urinary nitrate to nitrite

Leukocytes

* Leukocytes (white blood cells) usually indicate infection.
* Leucocyte esterase activity is due to presence of WBCs in urine while nitrites strongly suggest bacteriuria.

Normal Values

* Negative results for glucose, ketones, bilirubin, nitrites, leukocyte esterase and blood.
* Protein negative or trace.
* pH 5.5-8.0
* Urobilinogen 0.2-1.0 Ehrlich units

Handling and Storage of Strips

* Handling and Storage
o Keep strips in original container
o Do not touch reagent pad areas
o Reagents and strips must be stored properly to retain activity
+ Protect from moisture and volatile fumes
+ Stored at room temperature
o Use before expiration date

Procedure

* Dip strip briefly, but completely into well mixed, room temperature urine sample.
* Withdraw strip.
* Blot briefly on its side.
* Keep the strip flat, read results at the appropriate times by comparing the color to the appropriate color on the chart provided.

Sources of Error

* Timing - Failure to observe color changes at appropriate time intervals may cause inaccurate results.
* Lighting - Observe color changes and color charts under good lighting.
* QC - Reagent strips should be tested with positive controls on each day of use to ensure proper reactivity.
* Sample - Proper collection and storage of urine is necessary to insure preservation of chemical.

Sources of Error

* Testing cold specimens - would result in a slowing down of reactions; test specimens when fresh or bring them to RT before testing
* Inadequate mixing of specimen - could result in false reduced or negative reactions to blood and leukocyte tests; mix specimens well before dipping
* Over-dipping of reagent strip - will result in leaching of reagents out of pads; briefly, but completely dip the reagent strip into the urine

Examination of Urine

Read more...

Blood Collection



Blood Collection

An overview of the process involved in collecting donor blood

Donor Screening
* Starts with the donor and first impressions are critical
* Clean, well lit donation facility from waiting room to collection area
* Pleasant, professional staff who can ask the appropriate questions, observe and interpret the responses, and ensure that the collection process is as pleasant as possible

Blood Bank versus Blood Center
* Confusion exists and terms are sometimes used inappropriately
* Blood bank in a hospital is also known as the transfusion service, performs compatibility testing and prepares components for transfusion
* Blood Center is the donation center, screens donors, draws donors, performs testing on the donor blood, and delivers appropriate components to the hospital blood bank

Standards, Regulations, Governing Bodies
* Strict guidelines exist and inspections are performed in both blood centers and blood banks to ensure the safety of the donors and patients
* Some or all of the following agencies may be involved:
o AABB – American Association of Blood Banks
o FDA – Food and Drug Administration
o CAP – College of the American Pathologists
o JCAHO - Joint Commission on the Accreditation of Hospital Organizations
o NCCLS – National Committee for Clinical Laboratory Standards

Donor Screening
* Medical History based on a standardized questionnaire obtains critical information about the donor’s health and risk factors which may make it unsafe for donation
* Physical Exam which includes blood pressure, temperature, pulse and screen for anemia are performed to ensure donor is healthy enough to donate.
* Two goals of screening
o Protect the health of the potential donor
o Protect the health of the potential recipient

Donor Registration
* Donor signs in
* Written materials are given to the donor which explains high risk activities which may make the donor ineligible
* Donor must be informed and give consent that blood will be used for others unless they are in a special donor category
* First time donors must provide proof of identification such as SS#, DL#, DOB, address and any other unique information.
* Repeat donors may be required to show DL or some other photo ID

Frequency of donation
* Whole blood or red blood cells 8 weeks
* Plateletpheresis – up to 24 times/year
* Plasmapheresis– once every 4 weeks, can be done twice a week
* Granulocytes

Medical History
* A thorough history is obtained each time
* Standardized universal questionnaire is used
* Questions are asked that are very intimate in nature but are critical in assessing HIV or HBV risks
* Medications the donor taking are present in plasma, may cause deferral
* Infections the donor has may be passed to recipient, may be cause for deferral

12 Month Deferral
* Any intimate sexual relations with HIV positive, HBV positive, hemophiliacs, drug users or individuals receiving drugs/money for sex.
* Recipient of blood, components or blood products such as coagulation factors
* Sexually transmitted disease-if acquired indicates safe sex not practiced and donor at risk for HIV and HBV
* Travel to malarial endemic country

Temporary Deferrals
* Certain immunizations
o 2 weeks -MMR, yellow fever, oral polio, typhoid
o 4 weeks -Rubella, Chicken Pox
o 2 months – small pox
* Pregnancy – 6 weeks upon conclusion
* Certain medications
o Proscar/Propecia, Accutain – 1 month
o Avodart – 6 months
o Soriatane – 3 years
o Tegison - permanent

Permanent Deferrals
* HIV, HBV, or HCV positive
* Protozoan diseases such as Chagas disease or Babesiosis
* Received human pituitary growth hormone
* Donated only unit of blood in which a recipient contracted HIV or HBV
* Was the only common donor in 2 cases of post-transfusion HIV or HBV in recipient
* Lived in a country where Creutzfeld-Jacob disease is prevalent
* Most cancers except minor skin cancer and carcinoma in-situ of the cervix
* Severe heart disease, liver disease

Helpful Hint
* Permanent deferral – any member of high risk group such as: HIV/HBV/HCV pos, drugs/sex for money, cancer, serious illness or disease, CJD, Chagas disease, Babesiosis
* 12 month deferral – sex with any high risk group, any blood exposure, recipient of blood/blood products, STD, jail/prison, rabies vaccine after exposure, HBIG, malaria
* Have to memorize: medications and vaccinations

Self-Exclusion
* Two stickers
o “Yes, use my blood”
o “No, do not use my blood”
* After interview the donor will place the appropriate bar coded label on the donation record
* If “no” selected the unit is collected, fully tested, but not used for transfusion
* Allows donors who know they are at risk to “save face” if pressured to donate by friends and family

Donor Categories
* “Allogeneic”, “homologous” and “random donor” terms used for blood donated by individuals for anyone’s use
* Autologous – donate blood for your own use only
* Recipient Specific Directed donation – donor called in because blood/blood product is needed for a specific patient
* Directed Donor – patient selects their own donors
* Therapeutic bleeding – blood removed for medical purposes such as in polycythemia vera. NOT used for transfusion.

Auto/Directed Blood Labels
Donor Categories
* Safest is autologous, blood is your own, no risk of disease acquisition
* Most dangerous is Directed Donor, you select a donor who may, unknown to you, be in a high risk category but feels obligated to follow through and donate

Blood Collection
* Materials used are sterile and single use.
* Most important step is preparing the site to a state of almost surgical cleanliness.
* Bacteria on skin, if present, may grow well in stored donor blood and cause a fatal sepsis in recipient
* Use 16-17 gauge needle to collect blood from a single venipuncture within 15 minutes
* Collect 450 +/- 45 mLs of blood

Donor Reactions
* Syncope (fainting)
o Remove needle immediately
* Hyperventilation
o Have donor rebreathe into paper bag.
* Nausea/vomiting
* Twitching/muscle spasms
* Hematoma
* Convulsions – rare, get immediate assistance
* Cardiac difficulties

Post-Phlebotomy Care
* Donor applies pressure for 5 minutes
* Check and bandage site
* Have donor sit up for few minutes
* Have donor report to refreshment area for additional 15 minutes of monitoring

Post-Phlebotomy Instructions
* Eat/drink before leaving
* Wait until staff releases you
* Drink more fluids next 4 hours
* No alcohol until after eating
* Refrain from smoking for 1 hour
* If bleeding continues apply pressure and raise arm
* Faint or dizzy sit with head between knees
* Abnormal symptoms persist contact blood center.
* Remove bandage

Testing Donor Blood
* CANNOT rely on previous testing
* Records must be kept for 5 years

Serological Testing
* ABO/D typing
* Antibody Screen – if positive, ID antibody, cannot make plasma products
* Antibodies to other blood group antigens which are present in the donor may react with recipient red cells resulting in a reaction.

Disease Testing
* Disease testing include:
o HBsAG
o HBc
o HCV
o HIV 1&2
o HTLV I/II
o RPR
o NAT for HIV-1, HCV & WNV

Results of Testing
* Tests for disease markers must be negative or within normal limits.
* Donor blood which falls outside these parameters must be quarrantined.
* Repeat testing, if still abnormal must dispose.

Transfusion Service Testing
* The only repeat testing required is:
o ABO on red cell products
o D typing (IS) on D negative red cell products
* Plasma products (FFP, CRYO, PLTS) do not require any testing.
* Donor samples must be stored at 1-6C for at least 7 days after transfusion
o ADSOL unit transfused today must save sprig for one week
o Many facilities will pull a sprig from each donor during processing and save all sprigs for 49 days, regardless of expiration of unit

Summary
* Blood collection starts with screening of the donor to:
o Ensure they are healthy enough to donate
o Ensure they do not have transmissible diseases
* Many organizations set standards and monitor all aspects of blood collection and administration.
* Collection of blood must be done in such a manner as to ensure sterility of the component.
* Testing of donor blood includes serological testing for ABO/D typing, antibody screening, and testing for markers indicating infection.
* The blood supply is NOT safe, only careful screening and testing can prevent, as much as possible, disease transmission.

Blood Collection

Read more...
All links posted here are collected from various websites. No video or powerpoint files are uploaded on this blog. If you are the original author and do not wish to display your content on this blog please Email me anandkumarreddy at gmail dot com I will remove it. The contents of this blog are meant for educational purpose and not for commercial use. If you use any content give due credit to the original author.

This site uses cookies from Google to deliver its services, to personalise ads and to analyse traffic. Information about your use of this site is shared with Google. By using this site, you agree to its use of cookies.

  © Blogger templates Newspaper III by Ourblogtemplates.com 2008

Back to TOP